Go Pro
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$386.26 -1.64 (-0.42%)
As of 03:58 PM Eastern

About Bio-Rad Laboratories Stock (NYSE:BIO)

Advanced

Key Stats

Today's Range
$376.20
$386.78
50-Day Range
$283.71
$391.29
52-Week Range
$236.73
$396.23
Volume
112,947 shs
Average Volume
319,671 shs
Market Capitalization
$10.33 billion
P/E Ratio
46.82
Dividend Yield
N/A
Price Target
$343.33
Consensus Rating
Hold

Company Overview

Bio-Rad Laboratories, Inc. is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions. Its life science tools support academic and pharmaceutical research, while its diagnostics solutions serve hospitals, reference laboratories and blood banks worldwide. The company places particular emphasis on product reliability, regulatory compliance and technical support for its diverse customer base.

Over its history, Bio-Rad has expanded through both internal development and strategic acquisitions, broadening its portfolio with products such as electrophoresis systems, imaging platforms, droplet digital PCR and automated blood-typing instruments. The firm is led by Norman Schwartz, who serves as chairman and chief executive officer, building on the legacy of its founders. Through continued investment in research and development, Bio-Rad aims to deliver innovative technologies that address evolving challenges in life science research and clinical diagnostics.

AI Generated. May Contain Errors.

Bio-Rad Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

BIO MarketRank™: 

Bio-Rad Laboratories scored higher than 33% of companies evaluated by MarketBeat, and ranked 730th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Rad Laboratories has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and no sell ratings.

  • Downside Risk

    Bio-Rad Laboratories has a consensus price target of $343.33, representing about 11.1% downside from its current price of $386.26.

  • Amount of Analyst Coverage

    Bio-Rad Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bio-Rad Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Rad Laboratories are expected to decrease by -4.20% in the coming year, from $9.28 to $8.89 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Rad Laboratories is 46.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.30.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Rad Laboratories is 46.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.99.

  • Price to Book Value per Share Ratio

    Bio-Rad Laboratories has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bio-Rad Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    7.13% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 4.82.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently decreased by 5.99%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bio-Rad Laboratories does not currently pay a dividend.

  • Dividend Growth

    Bio-Rad Laboratories does not have a long track record of dividend growth.

  • News Sentiment

    Bio-Rad Laboratories has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Bio-Rad Laboratories this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bio-Rad Laboratories to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    30.34% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Rad Laboratories' insider trading history.
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO Stock News Headlines

Anthropic’s confidential SEC filing — and the public ticker that holds it
Anthropic filed confidentially for an IPO, and its annualized revenue run rate reportedly surged to $65 billion in July - seven times last year's pace. One public ticker reportedly holds Anthropic alongside $190 billion Databricks and $61 billion Anduril - three private-company catalysts in a single brokerage trade. Alexander Green believes the next major catalyst could arrive as early as September 29, when The AI Conference begins in San Francisco.tc pixel
Q1 EPS Estimate for Bio-Rad Laboratories Lifted by Analyst
FY2026 Earnings Estimate for BIO Issued By Zacks Research
Bio-Rad Laboratories to Cut Jobs, Close Facilities
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $303.62 on January 1st, 2026. Since then, BIO shares have increased by 27.2% and is now trading at $386.26.

Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings results on Tuesday, August, 4th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.75 by $0.87. Bio-Rad Laboratories's quarterly revenue was down .1% on a year-over-year basis.
Read the conference call transcript
.

Bio-Rad Laboratories subsidiaries include these companies: Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and more.

Bio-Rad Laboratories' top institutional shareholders include California State Teachers Retirement System (22.80%), Assenagon Asset Management S.A. (0.87%), Wellington Management Group LLP (0.23%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.03%). Insiders that own company stock include Andrew J Last, Michael Crowley, Dara Wright and James Barry.
View institutional ownership trends
.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
8/04/2026
Today
9/04/2026
Wells Fargo 21st Annual Healthcare Conference
9/09/2026
Next Earnings (Estimated)
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:BIO
CIK
12208
Employees
7,450
Year Founded
1952

Price Target and Rating

High Price Target
$370.00
Low Price Target
$330.00
Potential Upside/Downside
-11.1%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$8.25
Trailing P/E Ratio
46.82
Forward P/E Ratio
41.62
P/E Growth
N/A
Net Income
$759.90 million
Net Margins
8.59%
Pretax Margin
13.53%
Return on Equity
3.54%
Return on Assets
2.48%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
3.14
Quick Ratio
2.33

Sales & Book Value

Annual Sales
$2.58 billion
Price / Sales
4.00
Cash Flow
$9.97 per share
Price / Cash Flow
38.76
Book Value
$268.30 per share
Price / Book
1.44

Miscellaneous

Outstanding Shares
26,740,000
Free Float
18,626,000
Market Cap
$10.33 billion
Optionable
Optionable
Beta
1.07

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NYSE:BIO) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners